Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
7.56
Dollar change
+0.12
Percentage change
1.61
%
Index- P/E- EPS (ttm)-0.53 Insider Own5.19% Shs Outstand353.41M Perf Week2.58%
Market Cap2.68B Forward P/E72.31 EPS next Y0.10 Insider Trans0.00% Shs Float336.18M Perf Month-7.47%
Income-187.24M PEG- EPS next Q-0.01 Inst Own0.30% Short Float0.02% Perf Quarter-25.55%
Sales788.57M P/S3.40 EPS this Y72.54% Inst Trans- Short Ratio0.80 Perf Half Y-34.20%
Book/sh3.41 P/B2.21 EPS next Y171.87% ROA-7.42% Short Interest0.05M Perf Year-21.90%
Cash/sh1.83 P/C4.13 EPS next 5Y- ROE-13.21% 52W Range7.11 - 13.49 Perf YTD-35.55%
Dividend Est.- P/FCF118.14 EPS past 5Y- ROI-11.16% 52W High-43.97% Beta1.36
Dividend TTM- Quick Ratio2.09 Sales past 5Y15.79% Gross Margin23.06% 52W Low6.33% ATR (14)0.25
Dividend Ex-DateJan 11, 2019 Current Ratio2.16 EPS Y/Y TTM-166.84% Oper. Margin-7.90% RSI (14)41.81 Volatility2.05% 2.09%
Employees4952 Debt/Eq0.52 Sales Y/Y TTM8.18% Profit Margin-23.74% Recom1.55 Target Price14.24
Option/ShortNo / Yes LT Debt/Eq0.39 EPS Q/Q-42.33% Payout- Rel Volume0.62 Prev Close7.44
Sales Surprise10.14% EPS Surprise-263.58% Sales Q/Q16.51% EarningsNov 08 BMO Avg Volume67.64K Price7.56
SMA200.20% SMA50-16.62% SMA200-27.19% Trades Volume42,224 Change1.61%
Date Action Analyst Rating Change Price Target Change
Jan-18-24Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-23-23Upgrade Morgan Stanley Equal-Weight → Overweight $12 → $16
Jun-16-23Downgrade BofA Securities Buy → Neutral $13
Jun-08-23Upgrade Citigroup Neutral → Buy
Apr-04-23Upgrade Morgan Stanley Underweight → Equal-Weight $11 → $12
Dec-09-22Initiated H.C. Wainwright Buy $12
Nov-16-22Downgrade Deutsche Bank Buy → Hold
Aug-10-22Downgrade Morgan Stanley Overweight → Underweight $23 → $16
Mar-02-22Resumed Cowen Outperform
Jan-07-22Resumed Citigroup Neutral
Feb-07-24 02:00AM
Jan-22-24 02:00AM
Jan-10-24 09:45AM
Jan-08-24 01:50AM
Jan-04-24 01:45AM
12:45PM Loading…
Jan-03-24 12:45PM
Dec-19-23 02:00AM
Dec-14-23 02:00AM
Dec-11-23 02:00AM
Dec-06-23 01:50AM
Nov-15-23 01:50AM
Nov-08-23 01:20AM
Nov-07-23 01:50AM
01:30AM
Nov-01-23 07:25AM
02:35AM Loading…
Oct-05-23 02:35AM
Sep-27-23 01:50AM
Sep-26-23 08:00AM
Aug-29-23 01:20AM
Aug-22-23 08:20AM
Jul-27-23 02:45PM
Jul-11-23 08:00AM
01:50AM
Jul-05-23 01:50AM
Jun-29-23 02:00AM
Jun-20-23 11:30AM
Jun-05-23 01:50AM
Jun-02-23 02:00AM
May-12-23 06:30PM
May-09-23 02:55PM
02:30PM Loading…
02:30PM
Apr-24-23 04:05PM
Apr-10-23 08:15AM
Apr-07-23 09:20AM
Mar-28-23 05:20AM
01:30AM
Mar-24-23 03:00AM
Mar-21-23 07:10AM
Mar-16-23 03:05AM
Feb-10-23 02:00AM
Feb-09-23 02:00AM
Feb-07-23 02:00AM
Jan-26-23 02:00AM
Jan-10-23 07:00AM
Dec-16-22 03:40AM
Nov-12-22 01:32AM
Nov-10-22 11:51PM
Nov-09-22 08:00AM
01:20AM
Nov-08-22 11:02PM
03:07AM
Nov-03-22 07:15AM
03:00AM
Nov-02-22 03:00AM
Oct-28-22 03:20AM
Oct-25-22 01:50AM
Oct-18-22 09:03AM
02:00AM
Oct-17-22 07:15AM
07:00AM
Sep-21-22 10:06AM
Sep-20-22 01:50AM
Sep-16-22 09:25AM
Sep-01-22 07:33AM
Aug-25-22 01:50AM
Aug-11-22 01:40AM
Aug-10-22 07:54AM
01:55AM
Aug-04-22 05:30AM
Jul-06-22 01:50AM
Jul-05-22 01:50AM
Jun-22-22 10:45AM
Jun-15-22 10:47AM
Jun-14-22 10:23AM
01:50AM
May-30-22 02:00AM
May-19-22 01:50AM
May-17-22 11:33AM
07:00AM
01:50AM
May-10-22 10:55AM
10:45AM
May-04-22 08:45AM
Apr-25-22 04:03PM
11:47AM
Apr-22-22 09:23AM
Apr-12-22 01:45AM
Apr-08-22 01:55AM
Apr-05-22 08:55AM
Apr-04-22 11:44AM
Mar-21-22 03:00AM
Mar-02-22 01:50AM
Mar-01-22 01:50AM
Feb-04-22 02:44PM
07:45AM
Jan-25-22 01:55AM
Jan-18-22 03:53AM
02:00AM
Jan-11-22 02:00AM
Jan-03-22 01:55AM
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.